Intellia Therapeutics raises $55 million via stock private placements

Company sells 3.06 million shares at $18.00 to Novartis, Regeneron

By Marisa Wong

Morgantown, W.Va., May 17 – Intellia Therapeutics, Inc. raised $55 million from two separate and concurrent private placements of common stock that closed May 11, according to an 8-K filed Tuesday with the Securities and Exchange Commission.

The company sold 277,777 shares and 2,777,777 shares at $18.00 per share to Novartis Institutes for BioMedical Research, Inc. and Regeneron Pharmaceuticals, Inc., respectively.

The private placements closed on the same day as the company’s initial public offering, in which the company sold 6.9 million shares at $18.00 each.

The gene editing company is based in Cambridge, Mass.

Issuer:	Intellia Therapeutics, Inc.
Issue:	Common stock
Amount:	$54,999,972
Shares:	3,055,554
Price:	$18.00
Warrants:	No
Investors:	Novartis Institutes for BioMedical Research, Inc. (for 277,777 shares) and Regeneron Pharmaceuticals, Inc. (for 2,777,777 shares)
Settlement date:	May 11
Stock symbol:	Nasdaq: NTLA
Stock price:	$24.98 at close May 16
Market capitalization:	$926.9 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.